logo-loader
Scancell Holdings PLC

Board Appointment

/**/ sup{font-size:80%}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ag{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ag{}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.bv{font-size:10.0pt;font-family:"Arial","sans-serif"}p.by{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Courier New";color:black;font-weight: bold; text-align: center}span.bt{font-family:"Arial","sans-serif"}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center}span.bq{font-size:10.0pt;font-family: "Arial","sans-serif"}span.bo{font-family:"Arial","sans-serif"; letter-spacing:-.1pt}p.ca{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Courier New";color:black;font-weight: bold} span.bn{font-family:"Arial","sans-serif";color:windowtext}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.bk{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}span.bj{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}table.ce{width:481.9pt}td.be{width:243.0pt;padding:0cm 0cm 0cm 0cm}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm}td.bd{width:238.5pt;padding:0cm 0cm 0cm 0cm} p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}table.ch{margin-left:-5.4pt;border-collapse:collapse}td.ba{width:247.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.az{width:74.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.ax{width:127.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.ay{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black;background:white}tr.at{height:10.4pt}td.aw{width:247.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.4pt}td.av{width:74.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.4pt}td.au{width:127.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:10.4pt} tr.ap{height:11.8pt}td.as{width:247.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.8pt}td.ar{width:74.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.8pt}td.aq{width:127.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.8pt}p.ci{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}p.cj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-autospace: none}span.al{font-size:10.0pt; font-family:"Arial","sans-serif";color:black}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt; line-height:normal;text-autospace:none} span.ai{font-size:10.0pt; font-family:Symbol;color:black}span.cn{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;font-size:10.0pt;font-family:"Arial","sans-serif"} /**/
RNS Number : 5255C
Scancell Holdings Plc
18 June 2019
 

18 June 2019

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Board Appointment

 

Scancell, the developer of novel immunotherapies for the treatment of cancer, announces that, further to the Company's announcement on 13 June 2019, Martin Diggle, Co-Founder and Portfolio Manager of Vulpes Investment Management, has been appointed to the Company's Board of Directors (the "Board") as a Non-Executive Director with immediate effect.

 

Mr Diggle has over 30 years' experience in investment banking and fund management and has been an investor in life sciences and biotechnology companies for nearly 20 years. He is also an expert in Emerging Markets and Russia, where he was previously a partner and director of UBS Brunswick. He holds a Master's Degree in Philosophy, Politics and Economics from University of Oxford.

 

 

Additional Information

In accordance with the AIM Rules, the following information required to be disclosed in relation to Martin Diggle  is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.

 

Full name and age

 

Martin Henry Diggle, 57 years old

 

Current beneficial shareholding in the Company

 

Martin Diggle is a director and partner in Vulpes Investment Management and manages the Vulpes Life Sciences Fund which is the registered holder of 77,559,311 ordinary shares, representing approximately 16.67 per cent. of Scancell's ordinary share capital. 

 

Current Directorships

Past Directorships in the previous five years

Chronos Therapeutics Limited                                                                           

N/A

Oxford BioMedica plc


Proteome Sciences plc


 

For Further Information:

 

Scancell Holdings plc



Dr John Chiplin, Chairman


+44 (0) 20 3727 1000

Dr Cliff Holloway, CEO






Panmure Gordon (UK) Limited

(Nominated Adviser and Corporate broker)



Freddy Crossley/Emma Earl


+44 (0) 20 7886 2500




FTI Consulting

Simon Conway/Natalie Garland-Collins


+44 (0) 20 3727 1000

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

 

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

 

·      SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

 

·      SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

 

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

 

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

 

For further details, please see our website:  www.scancell.co.uk

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAUBVVRKVANAAR

Quick facts: Scancell Holdings PLC

Price: £0.07

Market: LSE
Market Cap: £33.74 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital...

Richard Goodfellow Presents on Behalf of Scancell at the Biotech Capital Conference 

on 03/08/2016